Higher MIND Diet Adherence Cuts Risk for Alzheimer Disease and Related Dementias
By Lori Solomon HealthDay Reporter
MONDAY, June 2, 2025 -- Higher adherence to the MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet in mid to late life is associated with a reduced risk for Alzheimer disease and related dementias (ADRD), according to a study presented at NUTRITION 2025, the annual meeting of the American Society for Nutrition, held from May 31 to June 3 in Orlando, Florida.
Song-Yi Park, Ph.D., from the University of Hawaii at Manoa, and colleagues examined the MIND diet in relation to late-onset ARD risk across five racial and ethnic groups participating in the Multiethnic Cohort Study. The analysis included data from participants (45 to 75 years) measured at baseline and at 10-year follow-up.
The researchers observed a modest decrease in ADRD risk in the highest versus the lowest MIND diet score group (hazard ratio [HR], 0.91). The inverse association varied by race and ethnicity, suggesting stronger protection among African American, Latino, and White participants than for Japanese-American or Native Hawaiian groups. MIND diet score improvement over 10 years was associated with a lower risk overall (hazard ratio, 0.75) compared with groups with the greatest increase (≥1 standard deviation increase versus ≥1 standard deviation decrease), with an inverse association seen for all racial and ethnic groups except Native Hawaiian. The inverse association was consistent for the younger (younger than 60 years at baseline) and older (60 years and older) age groups.
"Our study findings confirm that healthy dietary patterns in mid to late life and their improvement over time may prevent Alzheimer's and related dementias," Park said in a statement. "This suggests that it is never too late to adopt a healthy diet to prevent dementia."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...
Dementia Risk Does Not Differ With GLP-1 RAs, DPP4is for Seniors With T2DM
MONDAY, July 21, 2025 -- For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.